| Similar Articles |
|---|
 |
The Motley Fool
June 22, 2005 |
The Bond Scoop Ever wondered how bonds work? Here's the answer.   |
The Motley Fool
November 2, 2010
Eric Dutram |
Tuesday's ETF to Watch: iShares Israel ETF (EIS) TEVA reports earnings. |
The Motley Fool
May 23, 2006
Stephen D. Simpson |
Howdy, Partner If you want to invest overseas, sometimes you have to look in the lonely, largely untouched corners. Take Partner Communications, one of Israel's largest telecommunications firms; it's virtually ignored by U.S. analysts. |
The Motley Fool
September 7, 2006 |
Long Bonds and Zero Coupons Think of bonds as loans -- and perhaps consider investing in some. |
The Motley Fool
February 28, 2006
Stephen D. Simpson |
Still Waiting for Teva to Stumble This leading Israeli generics firm hasn't seen a stock pullback of any consequence since mid- to late 2004. And while fourth-quarter results weren't fabulous, they were good enough given the circumstances |
The Motley Fool
April 23, 2007
Selena Maranjian |
Bond Basics Get the scoop on everything from long bonds to T-bills. |
The Motley Fool
September 30, 2011
Brian Orelli |
When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs. |
BusinessWeek
December 20, 2004 |
Tightening Israeli-Egyptian Ties Four free-trade zones will be created in Egypt as a result of a deal to be signed by Israel, Egypt, and the U.S. on Dec. 14. |
The Motley Fool
February 2, 2004
Selena Maranjian |
A Bond by Any Other Name Ever wonder what people mean by "zero coupon" and "long" bonds? |
The Motley Fool
May 3, 2011
Brian Orelli |
Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon. |
AskMen.com
Michael Estrin |
Investing In Bonds Having some bonds in your portfolio is not only a good way to make money, it's also a great way to diversify. Here's what you need to know before you invest in the bond market. |
The Motley Fool
May 5, 2010
Brian Orelli |
Teva's Double-Edged Sword Nice quarter, but where will future growth come from? |
BusinessWeek
September 9, 2010
Bhaktavatsalam et al. |
Israel Gets an Upgrade, and Investors Depart Now that it's a developed market rather than an emerging one, Harvard, T. Rowe Price, and others are pulling out |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
BusinessWeek
November 3, 2003
Diane Brady |
Biotech: Teva's Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market. |
BusinessWeek
September 20, 2004
Neal Sandler |
Why Israel Is A Land Of Tech Promise -- Again After a years-long slump, Israel is seeing a slew of high-tech IPOs, mergers, and new startups. |
The Motley Fool
March 7, 2005 |
Bonds and Interest Rates Bond prices move in strange ways -- learn why. |
BusinessWeek
November 11, 2010
Jonathan Ferziger et al. |
Speed Dial: Benjamin Netanyahu Israel's Prime Minister talks about growth. |
The Motley Fool
November 8, 2006
Brian Lawler |
Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong. |
The Motley Fool
November 3, 2010
Brian Orelli |
Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits. |
The Motley Fool
August 1, 2005
Stephen D. Simpson |
Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance. |
The Motley Fool
February 18, 2009
Brian Orelli |
Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens. |
The Motley Fool
May 10, 2006
Stephen D. Simpson |
Time to Make Room for Teva? This might be a rare chance to pick up a dominant company at an attractive price. Investors, take note. |
The Motley Fool
May 11, 2011
Jared Cummans |
Wednesday's ETF to Watch: iShares MSCI Israel Fund Teva Pharmaceuticals releases earnings today. |
The Motley Fool
May 7, 2008
Brian Orelli |
Teva's on a Tear The generic-drug maker can't be stopped. |
The Motley Fool
April 7, 2010
Rick Steier |
Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity. |
The Motley Fool
September 22, 2009
Robert Steyer |
Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge. |
The Motley Fool
May 5, 2009
Brian Orelli |
Generic Growth, Acquisition Style Sales at Teva Pharmaceuticals were up 22% year over year, but don't bust out the champagne just yet. |
The Motley Fool
May 12, 2011
Brian Orelli |
Teva's Mixed Bag Diversification sure helps. |
BusinessWeek
September 26, 2005 |
Israel Shakes Up Its Banking Sector The Israeli government hopes to get out of the banking business by yearend. |
The Motley Fool
September 25, 2008
Brian Orelli |
Teva Heads to Japan It's conquering the world, slowly but surely. But is it still a value play? |
The Motley Fool
July 30, 2008
Brian Orelli |
Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest. |
The Motley Fool
February 15, 2005
Stephen D. Simpson |
Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma. |
National Real Estate Investor
September 1, 2004
Hortense Leon |
Israeli Investors Flock to South Florida When Africa-Israel Investments and Brooklyn developer Shaya Boymelgreen announced in July that they were planning to build $1.5 billion of residential and office development near downtown Miami and on South Beach, South Floridians took notice. |
Chemistry World
December 2, 2013
Maria Burke |
Compromise puts Israel on course to join Europe's science program Israel and the EU have resolved the diplomatic dispute that looked set to shut out Israeli research universities and technology companies from Europe's flagship science program. |
BusinessWeek
May 27, 2010
Charlie Rose |
Charlie Rose Talks to Bashar al-Assad Syria's President on what the U.S. doesn't understand about the Mideast and the prospects for peace. |
The Motley Fool
November 5, 2004
Roger Nusbaum |
The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy. |
Entrepreneur
August 2005
Mark Henricks |
Promised Land Working with an Israeli firm may not be as easy as dealing with one across town or even across the United States, but U.S. companies are finding new opportunities by partnering with Israeli firms. |
BusinessWeek
February 23, 2004
Kripalani & Sandler |
Building Fences -- And Growing Closer From security to information technology, business ties between India and Israel are proliferating |
The Motley Fool
February 17, 2010
Brian Orelli |
This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it. |
Salon.com
January 4, 2001
Flore de Preneuf & Daryl Lindsey |
"I hope he will be better than his father" Israelis worry, and Palestinians hope, that a new Bush administration will be tougher on them than Clinton was... |
Registered Rep.
July 1, 2004
Robin Penfold |
Challenging Assumptions It's possible that, for the first time in any living person's career, U.S. stocks will not perform as well as bonds in the next couple of decades. |
The Motley Fool
August 28, 2007
Brian Orelli |
Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note. |
Financial Planning
July 1, 2007
Matthew Posner |
The Bond Buyer "Kicker" or "cushion" bonds provide benefits of which the buy-and-hold investor may not be aware. |
The Motley Fool
January 5, 2004
Mathew Emmert |
Broken Bonds Even if you've just experienced a painful breakup with the stock market, don't go falling in love with bonds just because you're on the rebound. The plain truth is that looking for love in today's bond market could lead to another broken heart. |
BusinessWeek
May 2, 2005 |
Tensions Over Israeli Arms Sales To China Israeli arms deals with China are continuing to make waves in relations between Jerusalem and Washington. |
The Motley Fool
August 10, 2005 |
What's a Bond? A bond is a loan from you to a company or government. If a company issues bonds, it's borrowing cash and promising to pay it back at a certain rate of interest. |
The Motley Fool
September 9, 2010
Jim Mueller |
Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker. |
The Motley Fool
July 28, 2009
Brian Orelli |
All Growth, All the Time This generic-drug maker is no value play. |
The Motley Fool
April 13, 2010
Brian Orelli |
Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development. |
